**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 82433

**Manuscript Type:** MINIREVIEWS

**Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?**

Janota B *et al*. Hypothyroidism and NAFLD: A coincidence or a relationship?

Barbara Janota, Elżbieta Szczepańska, Brygida Adamek, Ewa Janczewska

**Barbara Janota, Brygida Adamek, Ewa Janczewska,** Department of Basic Medical Sciences, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Bytom 41-902, Poland

**Elżbieta Szczepańska,** Department of Human Nutrition, Department of Dietetics, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Zabrze 41-808, Poland

**Author contributions:** Janota B collected data, wrote, and supervised the paper; Janczewska E wrote and supervised the paper; Szczepańska E, Adamek B wrote the paper.

**Corresponding author: Ewa Janczewska, DSc, MD, PhD, Adjunct Professor,** Department of Basic Medical Sciences, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Piekarska 18, Bytom 41-902, Poland. ejanczewska@sum.edu.pl

**Received:** December 18, 2022

**Revised:** February 17, 2023

**Accepted:** April 6, 2023

**Published online:** May 27, 2023

**Abstract**

Non-alcoholic fatty liver disease (NAFLD) is a global problem. It may be caused by metabolic and hormonal disorders, including hypothyroidism. However, non-thyroid causes of NAFLD in people with hypothyroidism, including improper eating behavior and low physical activity, should be acknowledged.  This study aimed to present the current literature on whether the development of NAFLD is related to hypothyroidism or a typical consequence of an unhealthy lifestyle in people with hypothyroidism. The results of previous studies do not allow for an unequivocal determination of the pathogenetic relationship between hypothyroidism and NAFLD. Important non-thyroid-initiating factors include providing too many calories in relation to requirements, consuming excessive amounts of monosaccharides and saturated fats, being overweight, and maintaining low physical activity levels. The recommended nutritional model for both hypothyroidism and NAFLD may be the Mediterranean diet, which is rich in fruits and vegetables, polyunsaturated fatty acids, and vitamin E.

**Key Words:** Non-alcoholic fatty liver disease; Hypothyroidism; Lifestyle; Exercise; Feeding behavior; Body weight

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Janota B, Szczepańska E, Adamek B, Janczewska E. Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship? *World J Hepatol* 2023; 15(5): 641-648

**URL:** <https://www.wjgnet.com/1948-5182/full/v15/i5/641.htm>

**DOI:** https://dx.doi.org/10.4254/wjh.v15.i5.641

**Core Tip:** Non-alcoholic fatty liver disease affects 25% of the adult population worldwide; however, the causes of the disease remain unclear. This review answers the question of whether the development of non-alcoholic fatty liver disease is related to hypothyroidism or whether it is a typical consequence of an unhealthy lifestyle in people with hypothyroidism.

**INTRODUCTION**

Global statistics indicate an increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in society[1]. Currently, this disease affects approximately 25% of the adult population worldwide. It is often diagnosed in developed countries and is the second most common indication for liver transplantation[2].

The etiology of NAFLD is complex. NAFLD may be a result of excessive body weight, obesity, or carbohydrate and lipid metabolism disorders[3]. NAFLD is defined as a hepatic manifestation of metabolic syndrome[3,4]. The disorders mentioned are serious problems, which are related to improper eating habits and low physical activity, but may also have endocrine causes[5,6]. The most frequently described associations between NAFLD and endocrinopathies are polycystic ovary syndrome (PCOS) (PubMed: NAFLD PCOS - 93 publications in the last 5 years) and primary and secondary hypothyroidism (PubMed: NAFLD hypothyroidism - 86 publications in the last 5 years), which are the subject of the authors' considerations[7,8]. The accumulation of fatty compounds in the liver is associated with abnormal concentrations of cortisol, insulin, thyroxine, somatotropin, testosterone, and prolactin, which may be abnormal in PCOS and/or hypothyroidism[8]. The need for further research on thyroid-hepatic interdependence is still highlighted in publications from 2022. This is because of the insufficient amount of data available within the thematic scope[9-13].

Considering the relationship between non-alcoholic fatty liver disease, lifestyle, and endocrine disorders, including thyroid dysfunction, it is important to determine whether the development of NAFLD is related to hypothyroidism as its result or a typical consequence of an improper lifestyle of people with hypothyroidism. This study presents considerations within this scope based on the current literature.

**LITERATURE REVIEW**

This literature review of the PubMed electronic database included 54 scientific articles over 5 years and 11 articles published between 2012 and 2016, including meta-analyses, cohort, and experimental studies. The following words were used to search for publications between October 2022 and February 2023: NAFLD and hypothyroidism = 86 publications, NAFLD and physical activity = 1009 publications, NAFLD and lifestyle = 1258 publications, NAFLD and Mediterranean diets = 172 publications, and lipid metabolism and thyroid = 693 publications. The last search was conducted in February 2023.

**LIPID METABOLISM IN NORMAL PHYSIOLOGY AND NAFLD**

Hepatic lipid metabolism involves three substrate delivery mechanisms. The first is the absorption of fatty acids from chylomicrons formed during the absorption of lipids from food in the digestive system[14]. The second involves lipids stored in the adipocytes. Fatty acids supplied by food are stored as triglycerides in adipose tissue cells and in the liver. Triglyceride lipase affects the triglycerides in the adipose tissue, resulting in the release of fatty acids followed by their uptake by liver cells[14]. The third mechanism is de novo lipogenesis, in which hepatocytes absorb fatty acids due to the conversion of the consumed carbohydrates into fats[14].

Lipid metabolism in the liver can be classified into three transformations: oxidation of supplied fatty acids in the process of beta-oxidation, accumulation of fatty acids, or formation of protein complexes with fatty acid participation[14]. In NAFLD, fatty acid metabolism is disrupted. The accumulation of fatty compounds begins to increase, contrary to the synthesis and secretion of very-low-density lipoprotein (LDL) into the blood. *De novo* lipogenesis exceeds the efficiency of oxidation processes and the concentration of serum triglycerides of extrahepatic origin in the increases[14, 15]. NAFLD is a progressive disease that begins with simple NAFLD, which may coexist with non-alcoholic steatohepatitis (NASH). NASH may be associated with fibrosis, leading to cirrhosis of the organ and the development of hepatocellular carcinoma[16].

**THYROID MECHANISMS OF METABOLIC CONTROL**

Follicular thyroid cells produce and secrete thyroxine (T4) and triiodothyronine (T3) hormones. The control of their secretion depends on the concentrations of hormones of the hypothalamus (thyroliberin), and pituitary gland [tyrosine (TSH)]. The mechanism aimed at maintaining homeostasis is a negative feedback mechanism[17].

Thyroid hormones perform numerous functions, including metabolic control, maintenance of body temperature, regulation of hunger and satiety, and regulation of carbohydrate and lipid metabolism[18]. This is possible because of the localization of thyroid hormone receptors in the cells of many organs and tissues; for example, the liver (THR-beta), pancreas, adipose tissue (THR-alpha), and muscle tissue (THR-alpha)[18,19]. TSH receptors, which are located on thyroid cells, have also been located outside the thyroid gland in adipose tissue cells, hepatocytes, and ovaries[18,20].

Under the influence of thyroid hormones, the fat contained in adipocytes is broken down into free fatty acids, which are transported through the bloodstream to the hepatocytes by binding (1-L-fatty acid-binding protein and 36-CD36 fatty acid translocase) and transporting (fatty acid transport protein) proteins[19]. The function of these proteins is also regulated by thyroid hormones, which participate in de novo lipogenesis by enhancing gene expression, including the expression of Spot14[12,21]. Moreover, the activity of hepatic lipase, which breaks down fats into fatty acids, enabling their beta-oxidation, is dependent on the concentration of thyroid gland hormones[22].

**HYPOTHYROIDISM AND ITS EFFECTS ON LIPID METABOLISM**

Hypothyroidism is a disease in which the serum concentration of thyroid hormones is reduced[14,23]. This disease affects approximately 5% of the population[24]. Contributors of disease development include an insufficient supply of iodine, a component of thyroid hormones, or Hashimoto's disease. In the latter case, there is inflammatory lymphocytic infiltration and the production of antibodies against enzymes that enable the production of thyroid hormones, such as thyroid peroxidase and thyroglobulin[24]. Due to the formation of an insufficient amount of hormones, numerous disorders affecting the homeostasis of the body arise. The main common features of people with uncontrolled hypothyroidism are the occurrence of lipid disorders, increased blood cholesterol and triglyceride levels, and accumulation of fatty compounds in the liver[25,26]. Such disorders result from insufficient concentrations of thyroid hormones and excessive concentrations of TSH in the blood, which increase the production and secretion of T3 and T4 by the thyroid cells, according to the negative feedback effect. It should be noted that thyroxine supplementation significantly affects metabolism, causing an increase in the basic metabolic rate. This results in increased energy expenditure and, in the case of maintaining a negative caloric balance, may contribute to weight reduction[27].

In mouse models, elevated TSH levels in hypothyroidism have been observed to increase the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase in liver cells. This results in changes in cholesterol synthesis, which may lead to the accumulation of fatty compounds in the liver[28,29].

The regulation of lipid concentration in the body also occurs at a genetic level through transcription factors, including sterol regulatory element-binding protein (SREBP) and liver X receptor (LXR)[30,31]. LXR has also been detected in the liver, and is both a thyroid hormone receptor and a nuclear receptor. SREBP controls lipid synthesis, which is significantly influenced by thyroid hormone levels. The effect of the action of thyroid hormones on SREBP-2, an isoform of SREBP, is a decrease in the expression of the LDL receptor, which manifests as an increase in serum cholesterol levels. In cases of thyroid hormone deficiency, this situation is reversed[30].

In both overt and subclinical hypothyroidism, there is an increase in the concentration of angiopoietin-like proteins Angptl-3 and Angptl-8, which participate in lipid metabolism and inhibit the action of lipoprotein lipase. The weakened function of lipoprotein lipase can lead to fat accumulation in the liver and decrease LDL cholesterol breakdown. The results of studies on the occurrence of increased concentrations of Angplt3 and 8 are clear, and scientists suggest using these proteins in the detection of hypothyroidism, although high concentrations have also been observed in obesity and diabetes[32,33].

Fibroblast growth factor FGF-21, which is still under study, enhances the beta-oxidation of fatty acids in the liver (where it is produced) while slowing down the formation of triglycerides. In acute hypothyroidism caused by radioiodine treatment, there is an increase in FGF-21 concentration, which ultimately predisposes patients to hepatic steatosis by enhancing lipogenesis[34].

The control of hepatocyte autophagy is another function that involves thyroid hormones[35]. In autophagy within liver cells, NCoR1, a co-repressor of nuclear receptor 1 under typical conditions, is degraded. In hypothyroidism, beta-oxidation is reduced by affecting peroxisome proliferator-activated alpha receptor, resulting in an increase in de novo lipogenesis[36].

The influence of thyroid hormones on lipid metabolism and liver function is a topic widely described in the scientific literature, and control mechanisms include multilevel interactions at molecular and cellular levels[37]. These relationships are still being researched, proving the importance of the subject[38,39].

**NAFLD AS A RESULT OF METABOLIC DISORDERS CAUSED BY AN IMPROPER LIFESTYLE IN PEOPLE WITH HYPOTHYROIDISM**

The relationship between NAFLD and hypothyroidism has been the subject of population studies in several countries. These results are sometimes contradictory, although most indicate the existence of a relationship[40]. In a cohort study involving 81166 German residents, a strong relationship between the diseases was found[41]. In contrast, no associations were found in a study involving 10116 Spanish residents, similar to the results of a retrospective study conducted among 18544 Korean residents[42,43]. Therefore, it is important to consider the non-thyroid causes of NAFLD in patients with hypothyroidism. Possible associations were studied by Mansour-Ghanaei *et al*[44], who examined 333 Iranian patients with diabetes, lipid disorders, obesity, and PCOS. Participants who had additional NAFLD were also diagnosed with hypothyroidism significantly more often; had significantly higher body mass index (BMI) values; smoked cigarettes more frequently; had considerably higher concentrations of total cholesterol, glucose, uric acid, and abnormal eating habits, which are important due to the unquestionable adverse effects on the body[44].

Due to the association between NAFLD and numerous metabolic disorders resulting from an improper lifestyle habits, metabolic dysfunction - associated fatty liver disease (MAFLD) has been distinguished as concurrent liver dysfunction and metabolic syndrome[45]. In turn, metabolic syndrome often accompanies hypothyroidism[46]. Biochemical and elastography screening tests are important for detecting the presence of metabolic disorders and MAFLD in people with hypothyroidism[47].

***Proper eating behavior as an important element of NAFLD prevention***

A significant risk factor for NAFLD is improper eating behavior, resulting in an excessive supply of energy in the diet, excessive consumption of monosaccharides (especially fructose), and saturated fats[38]. The diet of patients diagnosed with NAFLD should primarily limit the supply of monosaccharides because they intensify de novo lipogenesis[48]. Their consumption should also be limited because of the prevalence of insulin resistance in people with NAFLD, which is also observed in people with hypothyroidism[49]. Thyroid hormones affect glucose metabolism in the liver by activating glucose transporter 2, resulting in the release of glucose into the bloodstream[50]. The above mechanism is disrupted by thyroid hormone deficiency[50]. Insulin resistance, an imbalance in the proportion of serum insulin and glucose concentrations, activates SREBP-1c, resulting in the intensification of de novo lipogenesis, leading to fatty liver[51]. The Mediterranean diet, rich in vegetables, polyunsaturated fatty acids, and vitamin E, may be the recommended nutritional model for both hypothyroidism and NAFLD because of its proven anti-inflammatory effect and low glycemic index, which are important in the case of insulin resistance[52-56].

***Proper body weight as an important element of NAFLD prevention***

Excessive body weight caused by an increased amount of adipose tissue is an abnormality that may contribute to the development of obesity - a serious disease in which metabolic disorders (including lipid disorders) are associated with endocrine disorders and have a negative impact on all areas of a patient's life[55,56]. Scientists have emphasized that excessive body weight and obesity predict a worse course of NAFLD[57,58]. Obesity is also associated with hypothyroidism, as proven in a cohort study of 9,011 Chinese residents. In addition, researchers proved that obesity in younger men was an independent risk factor for hypothyroidism, while in older men, metabolic disorders were a significant factor in its pathogenesis[56]. There is equivocal evidence of a high correlation between BMI and TSH concentration[59,60]. Such conclusions were reached by Amin *et al*[59], who examined the effect of weight reduction on thyroid function and NAFLD in obese Egyptian adolescents during an intervention. It has been calculated that for an increase in TSH of 10 mIU/L, the BMI increases by 5.28 kg/m2[59]. Decreased body weight, TSH concentration, and percentage of people with fatty liver have been observed after lifestyle modifications, including altered physical activity and eating habits among adolescents[59]. Du *et al*[60] who studied the effect of thyroid hormones on central obesity, showed a positive correlation between the central obesity index (waist-hip Ratio, WHR), level of TSH, and BMI. The results of this study indicate the association between thyroid hormones and body weight and body fat distribution, which is due to the hypometabolic state caused by a thyroid hormone deficiency[60].Researchers have suggested that hepatic steatosis may have a negative impact on thyroid function rather than hypothyroidism, which has a negative impact on liver function[61].

***Physical activity as an important element of NAFLD prevention***

According to studies on the impact of lifestyle on the development of NAFLD[62]. The positive effect of physical activity is manifested by body weight reduction and increased insulin sensitivity in cells[55,63]. Additionally, physical activity prevents muscle mass reduction, which is a risk factor for NAFLD[60]. Increasing the level of physical activity is also recommended for people without excessive body weight but with NAFLD, in whom the researchers believed the cause of the disease to be an elevated TSH concentration[63,64]. Moreover, in a Chinese population study, which included 5,154 people, hypothyroidism was significantly more common in people who did not undertake physical activity than in euthyroid people[65].

A summary of the above information about importance of proper lifestyle in people with hypothyroidism is presented in Figure 1.

**CONCLUSION**

Hypothyroidism and NAFLD coexist, although their interdependence is not a cause-and-effect relationship.

The pathomechanism of excessive fat accumulation in the liver is complex, and its important non-thyroid-initiating factors are as follows: (1) providing too many calories in relation to requirements; (2) consuming excessive amounts of monosaccharides and saturated fats; (3) being overweight; and (4) keeping a low physical activity level.

The results of the previous studies do not allow for an unequivocal determination of the pathogenetic relationship between hypothyroidism and NAFLD.

Further research is necessary to answer the questions posed in the title. Among the patients with coexisting NAFLD and hypothyroidism, environmental factors and those dependent on human choice are more important.

**REFERENCES**

1 **Lazarus JV**, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol* 2022; **19**: 60-78 [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4]

2 **Tokushige K**, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. *J Gastroenterol* 2021; **56**: 951-963 [PMID: 34533632 DOI: 10.1007/s00535-021-01796-x]

3 **Dietrich CG**, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? *World J Gastroenterol* 2021; **27**: 5803-5821 [PMID: 34629804 DOI: 10.3748/wjg.v27.i35.5803]

4 **Kasper P**, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. *Clin Res Cardiol* 2021; **110**: 921-937 [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7]

5 **Saklayen MG**. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep* 2018; **20**: 12 [PMID: 29480368 DOI: 10.1007/s11906-018-0812-z]

6 **Lonardo A**, Mantovani A, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. *Int J Mol Sci* 2019; **20** [PMID: 31212642 DOI: 10.3390/ijms20112841]

7 **Gariani K**, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. *Endocr Connect* 2021; **10**: R52-R65 [PMID: 33449917 DOI: 10.1530/EC-20-0490]

8 **Tanase DM**, Gosav EM, Neculae E, Costea CF, Ciocoiu M, Hurjui LL, Tarniceriu CC, Floria M. Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options. *Int J Mol Sci* 2020; **21** [PMID: 32824723 DOI: 10.3390/ijms21165927]

9 **Bikeyeva V**, Abdullah A, Radivojevic A, Abu Jad AA, Ravanavena A, Ravindra C, Igweonu-Nwakile EO, Ali S, Paul S, Yakkali S, Teresa Selvin S, Thomas S, Hamid P. Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know. *Cureus* 2022; **14**: e28052 [PMID: 36127957 DOI: 10.7759/cureus.28052]

10 **Von-Hafe M**, Borges-Canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-Moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review. *Metabolites* 2022; **12** [PMID: 35448486 DOI: 10.3390/metabo12040298]

11 **Yang EJ**, Choi BS, Yang YJ. Risk of Nonalcoholic Fatty Liver Disease Is Associated with Urinary Phthalate Metabolites Levels in Adults with Subclinical Hypothyroidism: Korean National Environmental Health Survey (KoNEHS) 2012-2014. *Int J Environ Res Public Health* 2022; **19** [PMID: 35328955 DOI: 10.3390/ijerph19063267]

12 **Lugari S**, Mantovani A, Nascimbeni F, Lonardo A. Hypothyroidism and nonalcoholic fatty liver disease - a chance association? *Horm Mol Biol Clin Investig* 2018; **41** [PMID: 30367792 DOI: 10.1515/hmbci-2018-0047]

13 **Gor R**, Siddiqui NA, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Malik M, Hamid P. Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand. *Cureus* 2021; **13**: e14858 [PMID: 34104598 DOI: 10.7759/cureus.14858]

14 **Mato JM**, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. *World J Gastroenterol* 2019; **25**: 3009-3020 [PMID: 31293337 DOI: 10.3748/wjg.v25.i24.3009]

15 **Ipsen DH**, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cell Mol Life Sci* 2018; **75**: 3313-3327 [PMID: 29936596 DOI: 10.1007/s00018-018-2860-6]

16 **Nabrdalik K**, Pokrzywnicka P, Nabrdalik-Leśniak D, Gumprecht J, Kwiendacz H, Gumprecht J. Amelioration of liver enzyme abnormalities and improvement in glucose control with pioglitazone in a patient with diabetes mellitus type 2 and nonalcoholic fatty liver disease. *Clin Diabetol* 2016; **5**: 199–202 [DOI: 10.5603/dk.2016.0034]

17 **Wang JJ**, Zhuang ZH, Shao CL, Yu CQ, Wang WY, Zhang K, Meng XB, Gao J, Tian J, Zheng JL, Huang T, Tang YD. Assessment of causal association between thyroid function and lipid metabolism: a Mendelian randomization study. *Chin Med J (Engl)* 2021; **134**: 1064-1069 [PMID: 33942801 DOI: 10.1097/CM9.0000000000001505]

18 **Walczak K**, Sieminska L. Obesity and Thyroid Axis. *Int J Environ Res Public Health* 2021; **18** [PMID: 34574358 DOI: 10.3390/ijerph18189434]

19 **Sinha RA**, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. *Nat Rev Endocrinol* 2018; **14**: 259-269 [PMID: 29472712 DOI: 10.1038/nrendo.2018.10]

20 **Martínez-Escudé A**, Pera G, Costa-Garrido A, Rodríguez L, Arteaga I, Expósito-Martínez C, Torán-Monserrat P, Caballería L. TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. *J Clin Med* 2021; **10** [PMID: 34209831 DOI: 10.3390/jcm10132907]

21 **Rudolph MC**, Wellberg EA, Lewis AS, Terrell KL, Merz AL, Maluf NK, Serkova NJ, Anderson SM. Thyroid hormone responsive protein Spot14 enhances catalysis of fatty acid synthase in lactating mammary epithelium. *J Lipid Res* 2014; **55**: 1052-1065 [PMID: 24771867 DOI: 10.1194/jlr.M044487]

22 **Brenta G**, Berg G, Miksztowicz V, Lopez G, Lucero D, Faingold C, Murakami M, Machima T, Nakajima K, Schreier L. Atherogenic Lipoproteins in Subclinical Hypothyroidism and Their Relationship with Hepatic Lipase Activity: Response to Replacement Treatment with Levothyroxine. *Thyroid* 2016; **26**: 365-372 [PMID: 26839156 DOI: 10.1089/thy.2015.0140]

23 **Wilson SA**, Stem LA, Bruehlman RD. Hypothyroidism: Diagnosis and Treatment. *Am Fam Physician* 2021; **103**: 605-613 [PMID: 33983002]

24 **Chiovato L**, Magri F, Carlé A. Hypothyroidism in Context: Where We've Been and Where We're Going. *Adv Ther* 2019; **36**: 47-58 [PMID: 31485975 DOI: 10.1007/s12325-019-01080-8]

25 **Liu H**, Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. *Endocr Connect* 2022; **11** [PMID: 35015703 DOI: 10.1530/EC-21-0002]

26 **Yan F**, Wang Q, Lu M, Chen W, Song Y, Jing F, Guan Y, Wang L, Lin Y, Bo T, Zhang J, Wang T, Xin W, Yu C, Guan Q, Zhou X, Gao L, Xu C, Zhao J. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. *J Hepatol* 2014; **61**: 1358-1364 [PMID: 25016220 DOI: 10.1016/j.jhep.2014.06.037]

27 **Johannsen DL**, Galgani JE, Johannsen NM, Zhang Z, Covington JD, Ravussin E. Effect of short-term thyroxine administration on energy metabolism and mitochondrial efficiency in humans. *PLoS One* 2012; **7**: e40837 [PMID: 22844412 DOI: 10.1371/journal.pone.0040837]

28 **Zhang X**, Song Y, Feng M, Zhou X, Lu Y, Gao L, Yu C, Jiang X, Zhao J. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation *via* AMP-activated protein kinase in the liver. *J Lipid Res* 2015; **56**: 963-971 [PMID: 25713102 DOI: 10.1194/jlr.M047654]

29 **Kerr TA**, Davidson NO. Cholesterol and nonalcoholic fatty liver disease: renewed focus on an old villain. *Hepatology* 2012; **56**: 1995-1998 [PMID: 23115010 DOI: 10.1002/hep.26088]

30 **Moslehi A**, Hamidi-Zad Z. Role of SREBPs in Liver Diseases: A Mini-review. *J Clin Transl Hepatol* 2018; **6**: 332-338 [PMID: 30271747 DOI: 10.14218/JCTH.2017.00061]

31 **Miao Y**, Warner M, Gustafsson JK. Liver X receptor β: new player in the regulatory network of thyroid hormone and 'browning' of white fat. *Adipocyte* 2016; **5**: 238-242 [PMID: 27386163 DOI: 10.1080/21623945.2016.1142634]

32 **Yang L**, Yin R, Wang Z, Wang X, Zhang Y, Zhao D. Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism. *Biomed Res Int* 2019; **2019**: 3814687 [PMID: 31380419 DOI: 10.1155/2019/3814687]

33 **Abu-Farha M**, Al-Khairi I, Cherian P, Chandy B, Sriraman D, Alhubail A, Al-Refaei F, AlTerki A, Abubaker J. Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D. *Lipids Health Dis* 2016; **15**: 181 [PMID: 27733177 DOI: 10.1186/s12944-016-0337-x]

34 **Szczepańska E**, Glinicki P, Zgliczyński W, Słowińska-Srzednicka J, Jastrzębska H, Gietka-Czernel M. FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism. *Front Endocrinol (Lausanne)* 2022; **13**: 900034 [PMID: 35909532 DOI: 10.3389/fendo.2022.900034]

35 **Sinha RA**, Yen PM. Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD. *Cell Biosci* 2016; **6**: 46 [PMID: 27437098 DOI: 10.1186/s13578-016-0113-7]

36 **Byrnes K**, Blessinger S, Bailey NT, Scaife R, Liu G, Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. *Acta Pharm Sin B* 2022; **12**: 33-49 [PMID: 35127371 DOI: 10.1016/j.apsb.2021.07.021]

37 **Mavromati M**, Jornayvaz FR. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD. *Int J Mol Sci* 2021; **22** [PMID: 34884625 DOI: 10.3390/ijms222312797]

38 **Duarte SMB**, Stefano JT, Vanni DS, Carrilho FJ, Oliveira CPMS. IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). *Arq Gastroenterol* 2019; **56**: 431-439 [PMID: 31721969 DOI: 10.1590/S0004-2803.201900000-67]

39 **Liao CJ**, Huang PS, Chien HT, Lin TK, Yeh CT, Lin KH. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. *Biomedicines* 2022; **10** [PMID: 35740254 DOI: 10.3390/biomedicines10061232]

40 **He W**, An X, Li L, Shao X, Li Q, Yao Q, Zhang JA. Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. *Front Endocrinol (Lausanne)* 2017; **8**: 335 [PMID: 29238323 DOI: 10.3389/fendo.2017.00335]

41 **Loosen SH**, Demir M, Kostev K, Luedde T, Roderburg C. Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 2021; **33**: e1008-e1012 [PMID: 33852514 DOI: 10.1097/MEG.0000000000002136]

42 **Martínez Escudé A**, Pera G, Arteaga I, Expósito C, Rodríguez L, Torán P, Caballeria L. Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population. *Med Clin (Barc)* 2020; **154**: 1-6 [PMID: 31153607 DOI: 10.1016/j.medcli.2019.03.018]

43 **Lee KW**, Bang KB, Rhee EJ, Kwon HJ, Lee MY, Cho YK. Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study. *Clin Mol Hepatol* 2015; **21**: 372-378 [PMID: 26770926 DOI: 10.3350/cmh.2015.21.4.372]

44 **Mansour-Ghanaei F**, Joukar F, Mobaraki SN, Mavaddati S, Hassanipour S, Sepehrimanesh M. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran. *Diabetes Metab Syndr* 2019; **13**: 1591-1596 [PMID: 31336526 DOI: 10.1016/j.dsx.2019.03.009]

45 **Haufe S**, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. *Clin Transl Gastroenterol* 2021; **12**: e00371 [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371]

46 **Teixeira PFDS**, Dos Santos PB, Pazos-Moura CC. The role of thyroid hormone in metabolism and metabolic syndrome. *Ther Adv Endocrinol Metab* 2020; **11**: 2042018820917869 [PMID: 32489580 DOI: 10.1177/2042018820917869]

47 **Pujia R**, Mazza E, Montalcini T, Arturi F, Brunetti A, Aversa A, Romeo S, Perticone M, Sciacqua A, Pujia A. Liver Stiffness in Obese Hypothyroid Patients Taking Levothyroxine. *Medicina (Kaunas)* 2022; **58** [PMID: 35888665 DOI: 10.3390/medicina58070946]

48 **Chen J**, Huang Y, Xie H, Bai H, Lin G, Dong Y, Shi D, Wang J, Zhang Q, Zhang Y, Sun J. Impact of a low-carbohydrate and high-fiber diet on nonalcoholic fatty liver disease. *Asia Pac J Clin Nutr* 2020; **29**: 483-490 [PMID: 32990607 DOI: 10.6133/apjcn.202009\_29(3).0006]

49 **Kizivat T**, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. *J Clin Transl Hepatol* 2020; **8**: 347-353 [PMID: 33083258 DOI: 10.14218/JCTH.2020.00027]

50 **Srivastava S**, Mathur G, Chauhan G, Kapoor P, Bhaskar P, Jain G, Chauhan G, Chopra M. Impact of Thyroid Dysfunction on Insulin Resistance: A Study from a Tertiary Care Center in India. *J Assoc Physicians India* 2021; **69**: 49-53 [PMID: 33527811]

51 **Worm N**. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. *Nutrients* 2020; **12** [PMID: 32384593 DOI: 10.3390/nu12051316]

52 **Anania C**, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. *World J Gastroenterol* 2018; **24**: 2083-2094 [PMID: 29785077 DOI: 10.3748/wjg.v24.i19.2083]

53 **Bellastella G**, Scappaticcio L, Caiazzo F, Tomasuolo M, Carotenuto R, Caputo M, Arena S, Caruso P, Maiorino MI, Esposito K. Mediterranean Diet and Thyroid: An Interesting Alliance. *Nutrients* 2022; **14** [PMID: 36235782 DOI: 10.3390/nu14194130]

54 **Semmler G**, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD/NASH: Beyond the obvious. *Liver Int* 2021; **41**: 2249-2268 [PMID: 34328248 DOI: 10.1111/liv.15024]

55 **Lin X**, Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. *Front Endocrinol (Lausanne)* 2021; **12**: 706978 [PMID: 34552557 DOI: 10.3389/fendo.2021.706978]

56 **Wang Y**, Lin H, Li Q, Guan L, Zhao M, Zhong F, Liu J, Yuan Z, Guo H, Song Y, Gao L, Zhao J. Association between different obesity phenotypes and hypothyroidism: a study based on a longitudinal health management cohort. *Endocrine* 2021; **72**: 688-698 [PMID: 33818715 DOI: 10.1007/s12020-021-02677-2]

57 **Lu FB**, Hu ED, Xu LM, Chen L, Wu JL, Li H, Chen DZ, Chen YP. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 491-502 [PMID: 29609501 DOI: 10.1080/17474124.2018.1460202]

58 **Polyzos SA**, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. *Metabolism* 2019; **92**: 82-97 [PMID: 30502373 DOI: 10.1016/j.metabol.2018.11.014]

59 **Amin MK**, Ali AI, Elsayed H. Impact of Weight Reduction on Thyroid Function and Nonalcoholic Fatty Liver among Egyptian Adolescents with Obesity. *Int J Endocrinol* 2022; **2022**: 7738328 [PMID: 35392248 DOI: 10.1155/2022/7738328]

60 **Du FM**, Kuang HY, Duan BH, Liu DN, Yu XY. Effects of thyroid hormone and depression on common components of central obesity. *J Int Med Res* 2019; **47**: 3040-3049 [PMID: 31144547 DOI: 10.1177/0300060519851624]

61 **Sharma R**. Nonalcoholic Fatty Liver Disease and Subclinical Hypothyroidism in Obese Children. *Indian J Pediatr* 2021; **88**: 425-426 [PMID: 33796992 DOI: 10.1007/s12098-021-03749-x]

62 **Caro-Sabido EA**, Larrosa-Haro A. Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity: A scoping review. *Rev Gastroenterol Mex (Engl Ed)* 2019; **84**: 185-194 [PMID: 31101468 DOI: 10.1016/j.rgmx.2019.02.001]

63 **van der Windt DJ**, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. *Gene Expr* 2018; **18**: 89-101 [PMID: 29212576 DOI: 10.3727/105221617X15124844266408]

64 **Ahadi M**, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. *J Gastroenterol Hepatol* 2021; **36**: 1497-1507 [PMID: 33217052 DOI: 10.1111/jgh.15353]

65 **Huang Y**, Cai L, Zheng Y, Pan J, Li L, Zong L, Lin W, Liang J, Huang H, Wen J, Chen G. Association between lifestyle and thyroid dysfunction: a cross-sectional epidemiologic study in the She ethnic minority group of Fujian Province in China. *BMC Endocr Disord* 2019; **19**: 83 [PMID: 31362731 DOI: 10.1186/s12902-019-0414-z]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 18, 2022

**First decision:** February 7, 2023

**Article in press:** April 6, 2023

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Jamali R, Iran; Shalaby MN, Egypt **S-Editor:** Wang JL **L-Editor:** A **P-Editor:** Cai YX

**Figure Legends**



**Figure 1 Non-alcoholic fatty liver disease prevention in people with hypothyroidism: importance of proper lifestyle.** The most important lifestyle elements to prevent the development of non-alcoholic fatty liver disease include: proper supply of energy in the diet, anti-inflammatory diet, lower consumption of monosaccharides, lower consumption of saturated fats, correct body weight, quitting smoking, increasing the physical activity level, reducing the amount of adipose tissue. NAFLD: Non-alcoholic fatty liver disease.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**